Clinical trials: ABPA
Severe Asthma, Allergic Bronchopulmonary Aspergillosis (ABPA)
Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
Asthma is severe when it cannot be controlled with maximum-dose inhaled therapies while management of comorbidities and other precipitating or aggravating factors has been optimized.
- Trial name
- MOSAIC (NCT05616338)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 4 people
- Sponsor
- University Hospital, Montpellier
Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks.
- Conditions
- Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Aspergillus Tracheobronchitis
- Trial name
- NCT05897294
- Testing
- Voriconazole Inhalation Powder
- Sponsor
- TFF Pharmaceuticals, Inc.
Allergic Bronchopulmonary Aspergillosis
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
The investigators hypothesize that a combination of prednisolone and itraconazole would significantly reduce the exacerbation rate at one-year of patients with acute allergic bronchopulmonary aspergillosis (ABPA) compared to…
- Trial name
- PICA (NCT06174922)
- Testing
- Prednisolone, Itraconazole
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
ABPA, Allergic Bronchopulmonary Aspergillosis
ML-Based ABPA Recurrence Prediction and Clinical Utility
This multicenter bidirectional cohort study aims to develop and externally validate a machine learning model for predicting the risk of acute exacerbation within 1 year in patients with allergic bronchopulmonary aspergillosis…
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Acute Exacerbation
- Trial name
- ABPA-ML (NCT07714863)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA).
- Trial name
- NCT04442269
- Testing
- dupilumab
- Where
- 50 sites in United States, Bulgaria and 8 more
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Thymus and Activation Regulated Chemokine
Role of Thymus-And Activation-Regulated Chemokine (TARC) In Diagnosis Of Allergic Bronchopulmonary Aspergillosis
This study aims to assess the value of TARC in diagnosis of allergic Bronchopulmonary Aspergillosis.
- Trial name
- NCT03267394
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
ABPA
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
The goal of this clinical trial is to learn about PUR1900 as an inhaled, antifungal therapeutic for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
- Trial name
- NCT05667662
- Testing
- Itraconazole Powder
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 8 people
- Sponsor
- Pulmatrix Inc.
Allergic Bronchopulmonary Aspergillosis, Severe Asthma
Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis
An open-label study will evaluate effects of Tezepelumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
- Trial name
- NCT07757841
- Testing
- Tezepelumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital